๐”– Scriptorium
โœฆ   LIBER   โœฆ

๐Ÿ“

37th Hemophilia Symposium Hamburg 2006: Epidemiology;Treatment of Inhibitors in Hemophiliacs; Hemophilic Arthropathy and Synovitis; Relevant Hemophilia Treatment 2006; Pediatric Hemostasiology; Free Lectures

โœ Scribed by I. Scharrer (editor), Wolfgang Schramm (editor)


Publisher
Springer
Year
2007
Tongue
English
Leaves
299
Edition
2008
Category
Library

โฌ‡  Acquire This Volume

No coin nor oath required. For personal study only.


๐Ÿ“œ SIMILAR VOLUMES


37th Hemophilia Symposium Hamburg 2006:
โœ I. Scharrer, Wolfgang Schramm ๐Ÿ“‚ Library ๐Ÿ“… 2007 ๐Ÿ› Springer ๐ŸŒ English

This book contains the contribution to the 37th Hemophilia Symposium, Hamburg 2006. The main topics are epidemiolgy, treatment of inhibitors in hemophiliacs, hemophilic arthropathy and synovitis, relevant hemophilia treatment 2006, and pediatric hemostasiology. The volume is rounded off by numerous

36th Hemophilia Symposium Hamburg 2005:
โœ Inge Scharrer, Wolfgang Schramm, G. Auerswald, A. Kurth, J. Oldenburg, W. Schram ๐Ÿ“‚ Library ๐Ÿ“… 2006 ๐ŸŒ English

This book contains the contribution to the 36th Hemophilia Symposium, Hamburg 2005. The main topics are epidemiolgy, hemophilia therapy, orthopedic treatment in hemophiliacs, hemostaseologic diagnosis and pediatric hemostaseology. The volume is rounded off by numerous free papers and posters on hemo

36th Hemophilia Symposium Hamburg 2005:
โœ Inge Scharrer, Wolfgang Schramm, G. Auerswald, A. Kurth, J. Oldenburg, W. Schram ๐Ÿ“‚ Library ๐Ÿ“… 2006 ๐ŸŒ English

This book contains the contribution to the 36th Hemophilia Symposium, Hamburg 2005. The main topics are epidemiolgy, hemophilia therapy, orthopedic treatment in hemophiliacs, hemostaseologic diagnosis and pediatric hemostaseology. The volume is rounded off by numerous free papers and posters on hemo

36th Hemophilia Symposium Hamburg 2005:
โœ Inge Scharrer (editor), Wolfgang Schramm (editor) ๐Ÿ“‚ Library ๐Ÿ“… 2006 ๐Ÿ› Springer ๐ŸŒ English

<span>About 31% of the patients with a factor VIII replacement therapy develop a factor VIII inhibitor.From these are 23% low-responder ( 5BE) [8].In the case of severe hemophilia B, about 10.5% of the patients develop inhibitory antibodies [9]. Anti-factor VIII-antibodies are also seen in 15-78% he